Get Free Delivery With No Minimum Order

ULTRA CRANBERRY 750/MG TAB 30/TAB
- Sku : I-031025
Key features
ULTRA CRANBERRY 750/MG TAB is a tablet supplement containing cranberry (Vaccinium macrocarpon) extract 750 mg standardized to A‑Type proanthocyanidins (PACs). It supports urinary tract health by helping to prevent the adherence of certain bacteria to urinary tract walls, suitable for adults seeking daily urinary support. Formulated as a concentrated cranberry extract tablet, it delivers a higher PAC content than cranberry juice for more consistent dosing and improved compliance. Each serving is 1 tablet; available in a 30-tablet pack.- Brand: ULTRA CRANBERRY
- Supplement Type: Herbal
- Active Compounds: Cranberry (Vaccinium macrocarpon) extract 750mg, standardized to provide A-Type Proanthocyanidins (PACs).
- Supplement Form: Tablet
- Serving Size: 1 Tablet
- Servings Per Container: 30
- Pack Size: 30 Tablets
- Primary Benefit: Supports urinary tract health by helping to prevent the adherence of certain bacteria to the urinary tract walls.
- Bioavailability Form: Cranberry extract tablet - a concentrated form providing a higher content of A-Type Proanthocyanidins (PACs) than cranberry juice, which are the key active compounds that prevent E. coli from adhering to the bladder wall, improving dosing consistency and compliance.
- Prescription Status: OTC
- Certification: SFDA registered (Registration No. 407210843); GMP manufactured by Thompson Capper Limited, United Kingdom.
- Manufacturer: THOMPSON CAPPER LIMITED
- Country of Origin: United Kingdom
- SFDA Registration No.: 407210843
- Shelf Life: 36 months
- Plant Source: Cranberry (Vaccinium macrocarpon)
- Standardized Extract: Standardized to provide A-Type Proanthocyanidins (PACs); clinical benchmark is 36mg PACs per daily dose.
Benefits & Uses
Primary Benefit
Supports urinary tract health by helping to prevent the adherence of certain bacteria to the urinary tract walls.
Health Claims
Helps reduce the risk of recurrent urinary tract infections; supports urinary tract health by inhibiting bacterial adhesion to urinary tract walls; provides antioxidant support.
Common Deficiency Symptoms
Not applicable - cranberry is not an essential nutrient; recurrent urinary tract infections may indicate insufficient intake in susceptible individuals.
Target Population
Women prone to recurrent urinary tract infections; adults seeking urinary tract health support; postmenopausal women.
Scientific Evidence Level
Moderate
Onset Timeline
Urinary anti-adhesion effects may occur within hours of ingestion; reduction in UTI recurrence is typically observed after 4-12 weeks of consistent use.
Usage & Dosage
Suggested Use
Take one tablet daily with water.
Serving Size
1 Tablet
Servings Per Container
30
Side Effects
Toxicity Risk
Low
Interactions
Synergistic Nutrients
D-Mannose (complementary anti-adhesion mechanism targeting a different bacterial adhesion pathway for urinary tract health); Vitamin C (urinary acidification support).
Special Populations
Target Population
Women prone to recurrent urinary tract infections; adults seeking urinary tract health support; postmenopausal women.
Storage & Patient Advice
SFDA Storage Conditions
store below 25°c
Science & Evidence
Bioavailability Form
Cranberry extract tablet - a concentrated form providing a higher content of A-Type Proanthocyanidins (PACs) than cranberry juice, which are the key active compounds that prevent E. coli from adhering to the bladder wall, improving dosing consistency and compliance.
Scientific Evidence Level
Moderate
Onset Timeline
Urinary anti-adhesion effects may occur within hours of ingestion; reduction in UTI recurrence is typically observed after 4-12 weeks of consistent use.
Food Sources
Cranberries, cranberry juice, cranberry sauce.
Product Information
Supplement Type
Herbal
Certification
SFDA registered (Registration No. 407210843); GMP manufactured by Thompson Capper Limited, United Kingdom.
Plant Source
Cranberry (Vaccinium macrocarpon)
Standardized Extract
Standardized to provide A-Type Proanthocyanidins (PACs); clinical benchmark is 36mg PACs per daily dose.
-1744229570.gif)



